Novartis India Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novartis India Ltd.
More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.
Big pharma appears to be resetting operations in India fueling some concerns of waning interest. In Vivo looks at what the realignment means or doesn’t.
Pfizer effects hundreds of field force job cuts in India as it rewires its commercialization approach and creates new roles leveraging its ‘digital core’, but industry experts suggest there is a complex mix of other factors at play as well.
Wider-ranging new draft rules suggest that physicians in India should not engage in educational activity sponsored by pharma and urges them to declare financial earnings and benefits received from industry via an affidavit. The Pink Sheet discusses with industry experts some of the nuances and seeming loopholes in the rules, currently in self-regulatory mode but with penalties proposed for violation.